Cibus Completes First Field Trials in UK for Pod Shatter Reduction in Winter Oilseed Rape
10 September 2024 - 9:00PM
Cibus, Inc. (Nasdaq: CBUS), a leading agricultural
technology company that develops and licenses plant traits to seed
companies for royalties, today announced that it has completed
initial field tests of its Pod Shatter Reduction (PSR) trait in the
United Kingdom. The initial data from these trials support Cibus’
continuing commercial development of its PSR trait in winter
oilseed rape. These trials represent an important progression in
the Company’s commercial development with the application of Cibus’
spring oilseed rape (canola) PSR trait to winter oilseed rape.
Simplified rules, introduced in 2022 by the UK
Department for the Environment, Food and Rural Affairs led to a
science-based and streamlined regulatory approach that enabled
Cibus’ PSR trait to be tested in winter oilseed rape under European
growing conditions for the first time.
Cibus is a leader in the development of complex
gene edited traits in plants like Pod Shatter Reduction in winter
oilseed rape. The Company uses its proprietary Rapid Trait
Development System™ (RTDS®), which includes
techniques such as Gene Repair Oligonucleotides (GRON) and
molecular scissors including Transcription activator-like effector
nucleases (TALENs), to develop these traits.
Dr. Jim Radtke, Senior Vice President of Product
Development at Cibus commented, “The results of these first PSR
field trials in winter oilseed rape are very encouraging. We’ve
been able to validate our existing PSR trait’s performance under
controlled environments now in UK field conditions. These results
pave the way for a second season of trials that are now
underway.”
Tony Moran, Senior Vice President of
International Development and Government Affairs at Cibus added,
“Pod shatter in winter oilseed rape can impact growers’
productivity and national food security. With potential yield
losses of 5% to 25%, we’re really excited to see our latest trait
tested in European growing conditions. The completion of the first
field trials in the UK is an important milestone for our European
seed partners and winter oilseed rape farmers. We look forward to
delivering the benefits of precision breeding tools to UK farmers
and ultimately the broader European agriculture community.”
About Cibus
Cibus is a leading independent plant trait
company that develops and licenses plant traits to seed companies
for royalties. Cibus is not a seed company, but rather a technology
company that uses its proprietary gene editing technology to
develop and commercialize plant traits at a fraction of the time
and cost of conventional breeding. Cibus’ strategy is focused on
commercializing productivity traits for the world’s major row crops
with large acreage such as: canola, rice, soybean, corn and wheat.
The Company targets traits that help manage farmers’ seed
productivity and sustainability challenges such as weeds, disease,
and insects. The United Nations estimates that the impacts from
these challenges cost the global economy approximately $300 billion
annually. Cibus has a current portfolio of six traits, three of
which are in commercial development and four of which are
multi-crop traits associated with weed management and disease,
including Sclerotinia resistance and a new weed management trait
which are in advanced greenhouse and field trial stages.
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of the safe harbor provisions of the
U.S. Private Securities Litigation Reform Act of 1995. In some
cases, you can identify these statements by forward-looking words
such as "anticipates," "believes," "continue," "estimates,"
"expects," "intends," "may," "might," "plans," "predicts,"
"projects," "should," "targets," "will," or the negative of these
terms and other similar terminology. Forward-looking statements in
this press release include, but are not limited to, statements
regarding the anticipated closing of the offering and the expected
use of the proceeds from the offering. Completion of the offering
is subject to numerous factors, many of which are beyond Cibus’
control, including, without limitation, market conditions, failure
to satisfy customary closing conditions and the risk factors and
other matters set forth in the prospectus supplement and
accompanying prospectus included in the registration statement and
the documents incorporated by reference therein. You are cautioned
not to place undue reliance on any forward-looking statements made
by Cibus’ management, which are based only on information currently
available to it when, and speak only as of the date, such statement
is made. Cibus does not assume any obligation to publicly provide
revisions or updates to any forward-looking statements, whether as
a result of new information, future developments or otherwise,
should circumstances change, except as otherwise required by
law.
CIBUS CONTACTS:
INVESTOR RELATIONSKaren
Troeberktroeber@cibus.com858-450-2636
Jeff Sonnek – ICRjeff.sonnek@icrinc.com
MEDIA RELATIONSmedia@cibus.com(619) 849-6009
Colin Sanfordcolin@bioscribe.com203-918-4347
Cibus (NASDAQ:CBUS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cibus (NASDAQ:CBUS)
Historical Stock Chart
From Sep 2023 to Sep 2024